Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Renalytix ( (GB:RENX) ) has provided an announcement.
Renalytix announced that interim Chief Financial Officer Joel Jung purchased 2,000 American Depositary Shares at $2.90 per ADS on 11 February 2026, increasing his interest to 308,855 ordinary shares, or about 0.07% of the company’s issued share capital. The insider share purchase may be viewed by investors as a signal of management confidence in the company’s prospects as it continues to deploy its kidneyintelX.dkd diagnostic across U.S. physician groups and health systems.
Renalytix’s kidneyintelX.dkd test has been used in over 15,000 patients, generating real-world data that show higher diagnosis, prognosis and treatment rates in populations where it is deployed. With full Medicare reimbursement at $950 per reportable result and endorsement in international chronic kidney disease guidelines, the test strengthens Renalytix’s competitive position in the kidney disease diagnostics market and could support revenue growth and broader clinical adoption.
The most recent analyst rating on (GB:RENX) stock is a Sell with a £5.50 price target. To see the full list of analyst forecasts on Renalytix stock, see the GB:RENX Stock Forecast page.
Spark’s Take on GB:RENX Stock
According to Spark, TipRanks’ AI Analyst, GB:RENX is a Neutral.
The score is held down primarily by weak financial performance (large losses, negative equity, and ongoing cash burn) and a bearish technical trend (price below key moving averages and negative MACD). Positive corporate updates and oversold signals provide some support, but they do not offset current financial and trend risk.
To see Spark’s full report on GB:RENX stock, click here.
More about Renalytix
Renalytix plc is an AI-enabled in vitro diagnostics company focused on improving clinical management of kidney disease, particularly diabetic kidney disease. Its flagship product, kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test for early-stage risk assessment in chronic diabetic kidney disease and is commercially offered across select U.S. health systems.
Average Trading Volume: 498,288
Technical Sentiment Signal: Sell
Current Market Cap: £25.35M
For a thorough assessment of RENX stock, go to TipRanks’ Stock Analysis page.